Rinsho Shinkeigaku (Clinical Neurology)

Symposium 3

Selection and optimization of therapy for progressive type multiple sclerosis

Masaaki Niino, M.D., Ph.D.

Department of Clinical Research, Hokkaido Medical Center

Progressive type multiple sclerosis (MS) is usually divided into primary progressive MS (PPMS) and secondary progressive MS (SPMS), and the two types might be different pathologic entities. Some disease modifying therapies may be effective for progressive type MS. However, no class I evidence is currently available on initiating treatment for patients with either of the progressive types, and current treatment options for progressive type MS are limited. Moreover, there have been few curative treatments for various disabilities the disease cause. In the current situation, health-related quality of life (HRQOL) is an important issue for patients, and physicians should pay attention to improving this aspect of their life. In the near future, drugs for axonal regeneration and remyelination may become treatment options for patients with progressive type MS.
Full Text of this Article in Japanese PDF (160K)

(CLINICA NEUROL, 52: 1229|1230, 2012)
key words: multiple sclerosis, progressive type, therapy, quality of life

(Received: 25-May-12)